Friday, 16 October 2026European Markets

AXA NV23 Stock 11.69% Up On Thursday

Loading stream...

(vianews) - the market ended the session with axa nv23 (csnv.pa) jumping 11.69% to €28.66 on thursday, after five sequential sessions in a row of losses. cac 40 rose 0.11% to €7,139.25, after three sequential sessions in a row of gains, on what was a somewhat positive trend exchanging session today.

axa nv23's last close was €25.66, 2.6% higher than its 52-week high of €25.01.

about axa nv23

axa sa, through its subsidiaries, provides insurance, asset management, and banking services worldwide. the company operates through france, europe, asia, axa xl, international, and transversal & central holdings segments. it offers life and savings insurance products, such as savings and retirement, other health, and personal protection products. the company also provides property and casualty insurance products, including car, home, and personal or professional liability to individual and business clients; international insurance for large corporate clients in europe; and marine and aviation, as well as property and casualty reinsurance products. in addition, it offers asset management services in the areas of various asset classes, including equities, bonds, hedge funds, private equity, and real estate for the group's insurance companies and their clients, and retail and institutional clients. the company was founded in 1852 and is based in paris, france.

the company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 10.69%.

revenue growth

year-on-year quarterly revenue growth declined by 23.7%, now sitting on 107.73b for the twelve trailing months.

more news about axa nv23 (csnv.pa).

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com